Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphic Genetic Markers of the GABA Catabolism Pathway in Alzheimer's Disease.

Journal of Alzheimer's disease : JAD - 1 Jan 2020

Ciminelli Bianca Maria, Menduti Giovanna, Benussi Luisa, Ghidoni Roberta, Binetti Giuliano, Squitti Rosanna, Rongioletti Mauro, Nica Sabrina, Novelletto Andrea, Rossi Luisa, Malaspina Patrizia

Abstract excerpt

BACKGROUND: The compilation of a list of genetic modifiers in Alzheimer's disease (AD) is an open research field. The GABAergic system is affected in several neurological disorders but its role in AD is largely understudied. OBJECTIVE/METHODS: As an explorative study, we considered variants in genes of GABA catabolism (ABAT, ALDH5A1, AKR7A2), and APOE in 300 Italian patients and 299 controls. We introduce a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Cohort Studies

Share to gamma-Aminobutyric Acid

Share to Genetic Markers

Share to Metabolism

Share to Signal Transduction

Source

Identifiers

PMID: 32804142
DOI: 10.3233/JAD-200429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphic Genetic Markers of the GABA Catabolism Pathway in Alzheimer's Disease.PMID 32804142Read ↗

Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.Semantic proximity Read ↗

Pharmacogenetic Considerations in the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

Pharmacogenomics in Alzheimer's disease.Semantic proximity Read ↗

Exploring the Genetic Association of the ABAT Gene with Alzheimer's Disease.Semantic proximity Read ↗

The application of functional genomics to Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease PharmacogeneticsSemantic proximity Read ↗

Relationship Between Genetic Variants of ACAT1 and APOE with the Susceptibility to Dementia (SADEM Study).Semantic proximity Read ↗

Pharmacogenetics of Anxiety and Depression in Alzheimer’s DiseaseSemantic proximity Read ↗

Risk Variants in Three Alzheimer's Disease Genes Show Association with EEG Endophenotypes.Semantic proximity Read ↗

Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype).Semantic proximity Read ↗

Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics.Semantic proximity Read ↗

Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: a 90-month longitudinal study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.